Journal
JOURNAL OF LIPID RESEARCH
Volume 47, Issue 6, Pages 1203-1211Publisher
ELSEVIER
DOI: 10.1194/jlr.M500434-JLR200
Keywords
apolipoprotein C-I; apolipoprotein E; lipases; transgenic mouse models; lipoprotein lipase; very low density lipoprotein
Categories
Ask authors/readers for more resources
Previous studies have shown that overexpression of human apolipoprotein C-I (apoC-I) results in moderate hypercholesterolemia and severe hypertriglyceridemia in mice in the presence and absence of apoE. We assessed whether physiological endogenous apoC-I levels are sufficient to modulate plasma lipid levels independently of effects of apoE on lipid metabolism by comparing apolipoprotein E gene-deficient/apolipoprotein C-I gene-deficient (apoe2/2apoc12/2), apoe2/2apoc11/2, and apoe2/2apoc11/1 mice. The presence of the apoC-I gene-dose-dependently increased plasma cholesterol (+45%; P < 0.001) and triglycerides (TGs) (+137%; P < 0.001), both specific for VLDL. Whereas apoC-I did not affect intestinal [H-3] TG absorption, it increased the production rate of hepatic VLDL-TG (+35%; P < 0.05) and VLDL-[S-35] apoB (+39%; P < 0.01). In addition, apoC-I increased the postprandial TG response to an intragastric olive oil load (+120%; P < 0.05) and decreased the uptake of [H-3] TG-derived FFAs from intravenously administered VLDL- like emulsion particles by gonadal and perirenal white adipose tissue (WAT) (-34% and -25%, respectively; P < 0.05). As LPL is the main enzyme involved in the clearance of TG-derived FFAs by WAT, and total postheparin plasma LPL levels were unaffected, these data demonstrate that endogenous apoC-I suffices to attenuate the lipolytic activity of LPL. Thus, we conclude that endogenous plasma apoC-I increases VLDL-total cholesterol and VLDL-TG dose-dependently in apoe 2/2 mice, resulting from increased VLDL particle production and LPL inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available